ClinicalTrials.gg
CompletedNCT05573672EASe-GADUpdated Apr 4, 2025Results posted

Dietary Counselling Plus Omega-3 Supplementation in the Treatment of Generalized Anxiety Disorder

A Phase 2 interventional study of Dietary Counselling combined with Omega-3 Supplementation in Generalized Anxiety Disorder, sponsored by The Canadian College of Naturopathic Medicine. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-04.

Sponsored by The Canadian College of Naturopathic Medicine · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Generalized Anxiety Disorder with a site in Canada — 7 open to participants now, 11 under way, none of them phase 3. Generalized Anxiety Disorder · Canada.

Enrollment
26th of 45
50 · median 63
Started
2022
with 4 others
Phase 2
3 of 50
1 open now
Registered
43rd of 50
by date

Among the 50 studies in Generalized Anxiety Disorder with a site in Canada, this one is the 26th largest by enrollment of the 45 interventional ones that give a count, is one of 5 that started in 2022, is one of 3 in phase 2, and was the 43rd registered.

Generalized Anxiety Disorder

518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.

Browse Generalized Anxiety Disorder studies →

Open to participants now

7 of the 50 studies in Generalized Anxiety Disorder with a site in Canada are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 88 Generalized Anxiety Disorder studies recruiting now, 32 (36%) set no upper age limit and 54 (61%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Generalized Anxiety Disorder with a site in Canada, or all of them as a file.
02

Study summary

This study will assess the feasibility and acceptability of a combination intervention including dietary counselling and omega-3 fatty acid supplementation among women with generalized anxiety disorder. It will be randomized and wait-list controlled with 25 participants completing the 12-week intervention immediately and the other 25 participants completing the intervention after a 12-week wait period.

Read the detailed description

Generalized Anxiety Disorder (GAD) is a common mental health disorder involving high levels of worry or tension. The symptoms are persistent and distressing and interfere with an individual's functioning and quality of life. Clinical evidence suggests that nutritional interventions, based on the Mediterranean diet and omega-3 fatty acid supplementation improve the symptoms of depression. To date, the effect of diet change interventions on anxiety symptoms has not been studied in trials involving people with diagnosed anxiety disorders. The primary objective of this study is to test the feasibility and acceptability of a dietary counselling and omega-3 fatty acid supplementation intervention delivered to adult women with GAD. The secondary objectives include measuring changes in anxiety symptom severity, measuring changes in quality of life, measuring changes in biomarkers and evaluation of the components of the program.

This study is a randomized, wait-list controlled pilot trial delivering a 12-week, dietary counselling intervention and omega-3 supplementation to 50 adult women with GAD. Participant will complete seven individual counselling sessions which include nutrition education, personalized recommendations, mindful eating techniques, motivational interviewing, and goal setting. They will be provided with recipes, instructional videos, and food items. Questionnaires and blood work will be completed at baseline, after the wait period (for those in the wait-list group) and after the intervention. The questionnaires will measure changes in anxiety symptom severity, quality of life, diet quality, mindful eating behaviours, and self-efficacy and lab tests will measure changes in biomarkers of nutritional status. All participants will be asked to complete a brief satisfaction survey concerning the participant's level of satisfaction with the program, the aspects which were helpful or unhelpful, and opportunities for improvement. A sub-sample will be recruited to participate in a brief focus group in order to obtain more detailed qualitative responses about the participant experience and participant satisfaction. Additional information will be collected to characterize study participants including demographic information, body mass index, physical activity and food security.

Results from this study will lay the foundation for future large-scale studies in this area and may provide preliminary evidence of the role of diet counselling and omega-3 supplementation in the management of GAD.

03

Conditions studied

  • Generalized Anxiety Disorder

Keywords

  • anxiety
  • generalized anxiety disorder
  • nutrition
  • diet
  • omega-3
  • lifestyle
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A person aged 18-65 years who currently identifies as a woman.
  • Primary diagnosis of generalized anxiety disorder based on a clinical interview with a psychiatrist using the criteria.
  • Moderate to severe anxiety as defined as a Beck Anxiety Inventory score of 22 or higher.
  • Low quality diet as defined as a score of 8.5 or less on the MEDI-LITE tool.
  • All psychiatric medication, psychotherapy and natural health products stable for the past four weeks.
  • Established therapeutic relationship with a family doctor, psychiatrist, or clinical psychologist as their primary source of mental health care.
  • Ability to swallow capsules.
  • Ability to read in English and provide

Exclusion criteria

Exclusion Criteria:

  • Currently meets criteria for obsessive-compulsive disorder, bipolar disorder, a psychotic disorder, an eating disorder, or substance use disorder based on clinical interview with a psychiatrist.
  • Current high level of suicidality assessed by trial psychiatrist using the Columbia Suicide Severity Scale.
  • Starting or changing the dose of a psychiatric medication, psychotherapy, or natural health products in the past four weeks.
  • Severe food allergies, intolerances or aversions that would prevent the individual from modifying their diet (includes aversion to bovine gelatin which is a component of the fish oil supplement).
  • Current participation in a program, research study or treatment plan involving diet or lifestyle modification.
  • Baseline Omega Score of >5% (suggesting adequacy of omega-3 fatty acids).
  • Supplementation of greater than 4000IU of vitamin D daily for at least one month in the previous six months.
  • Allergy to fish or any of the non-medicinal ingredients in the study product.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    Immediate Start

    Dietary Counselling (7 bi-weekly sessions) plus omega-3 supplementation

    Combination Product: Dietary Counselling combined with Omega-3 Supplementation

  • No intervention
    Waitlist Control

    Participants will wait 12 weeks and then complete the same intervention as the Immediate Start arm.

Interventions

  • Combination productDietary Counselling combined with Omega-3 Supplementation

    Dietary Counselling: Seven, bi-weekly counselling sessions over 12-weeks conducted by a licensed Naturopathic Doctor. Each session will be 45-60 minutes in length. The recommendations will be based on the Mediterranean diet and the results of a recent scoping review which summarized the research related to diet and anxiety. The intervention will include motivational interviewing, mindful eating techniques, goal setting and action planning. A range of resources related to meal planning, recipes, cooking education, shopping lists and tracking sheets will be provided in an individualized manner. Dietary Supplement: AquaOmega High EPA Omega-3 capsules will be taken at a dose of four capsules, once daily (containing a total of 3456 mg of omega-3 fatty acids: 2659mg of Eicosapentaenoic acid (EPA), 532mg of docosahexaenoic acid (DHA), and 800IU of Vitamin D), with a meal.

06

What researchers measure

Primary outcomes

  1. Feasibility of Participant Recruitment and Intervention Delivery

    Feasibility will be assessed by measuring the time to recruit and enrol 50 participants. Additionally, we will compare the intervention protocol with the intervention activities delivered.

    Time frame: 8 months

  2. Acceptability of the Intervention by Study Participants

    Acceptability will be assessed by measuring the number of diet counselling sessions completed. Additionally, participants will be asked to complete a brief satisfaction survey concerning the participant's level of satisfaction with the program, the aspects which were helpful or unhelpful, and opportunities for improvement. A sub-sample will be recruited to participate in a brief focus group in order to obtain more detailed qualitative responses about the participant experience and participant satisfaction.

    Time frame: 12 weeks

Secondary outcomes

  1. Anxiety Symptom Severity: The Beck Anxiety Inventory

    The Beck Anxiety Inventory is a validated 21-item self-report inventory for measuring the severity of anxiety in participants with psychiatric illness. Answers to each item are given a score of 0 (not at all), 1 (mild), 2 (moderate) or 3 (severely), total scores range from 0 to 63 (minimal anxiety levels (0-7), mild anxiety (8-15), moderate anxiety (16-25), and severe anxiety (26-63)). The Beck Anxiety Inventory will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.

    Time frame: 12 weeks

  2. Diet Quality: MEDI-LITE Questionnaire

    MEDI-LITE is a validated questionnaire that measures daily and weekly consumption of food typical and non-typical to the Mediterranean diet. Typical Mediterranean diet foods are scored 2 for high consumption, 1 more moderate and 0 for low. Non-typical Mediterranean diet foods are scored 2 for low consumption, 1 for moderate and 0 for high. Scores range from 0 (low consumption) to 18 (high consumption). The MEDI-LITE questionnaire will be completed to assess adherence to the Mediterranean diet at baseline, after the wait period (for those in the waitlist group) and after the intervention.

    Time frame: 12 weeks

  3. Quality of Life: PROMIS-29 v2.1

    The PROMIS-29 is a validated scale using 4 items scored on a 1-5 scale on intensity to assess 7 health domains (physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities and pain interference). Higher score equals more of the concept being measured (e.g., more Fatigue, more Physical Function). PROMIS-29 will be used to assess quality of life at baseline, after the wait period (for those in the waitlist group) and after the intervention.

    Time frame: 12 weeks

  4. Mindful Eating Behaviour: Mindful Eating Questionnaire

    The MEQ is a 28-item scale that measures five factors associated with mindful eating (emotional responses, distraction, external cues, awareness and disinhibition). The questionnaire will be used to measure behaviour change and qualitatively assess the acceptability of the intervention. Each item is scored on a 1-4 scale, higher scores signify more mindful eating. The scores are added together and divided by the number of items answered to get a total summary score. The minimum score is 1 and the maximum score is 4. The MEQ will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.

    Time frame: 12 weeks

  5. Self Efficacy: General Self-Efficacy Scale

    The GSE is a 10-item validated questionnaire that measures an individual's belief in their ability to overcome and respond to difficult scenarios. Answers to each item are given a score of 0 (not at all true), 1 (barely true), 3 (moderately true) or 4 (exactly true), higher scores correlate to greater self-efficacy. The minimum score is 10 and the maximum score is 40. The GSE will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.

    Time frame: 12 weeks

  6. OmegaScore

    Summed EPA, DHA and DPA as a percentage of total fatty acids in whole blood as a measure of omega-3 status. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.

    Time frame: 12 weeks

  7. Fasting Cholesterol Panel

    Measures of serum cholesterol including LDL, HDL, triglycerides and total cholesterol. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.

    Time frame: 12 weeks

  8. Hemoglobin A1c

    Measure of the average blood sugar in the past 3 months. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.

    Time frame: 12 weeks

  9. Serum Vitamin C

    Measure of serum levels of vitamin C as an objective marker for fruit and vegetable intake. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.

    Time frame: 12 weeks

  10. Serum Beta-carotene

    Measure of serum levels of beta-carotene as an objective marker for fruit and vegetable. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.

    Time frame: 12 weeks

  11. C-reactive Protein

    CRP will be used to measure inflammation levels. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.

    Time frame: 12 weeks

  12. HOMA-IR

    Homeostatic Model Assessment of Insulin Resistance, calculated using fasting insulin and fasting glucose. Formula: fasting glucose (mg/dL) X fasting insulin (mU/L) / 405. A higher value suggests more insulin resistance. These blood tests and calculation will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.

    Time frame: 12 weeks

07

Results

Posted Apr 4, 2025

Participant flow

Participant flow — Overall Study
MilestoneImmediate StartWaitlist Control
Started2525
Completed2323
Not completed22

Outcome measures

PrimaryFeasibility of Participant Recruitment and Intervention Delivery

Feasibility will be assessed by measuring the time to recruit and enrol 50 participants. Additionally, we will compare the intervention protocol with the intervention activities delivered.

Time frame:
8 months
Reported as:
Number · months
Feasibility of Participant Recruitment and Intervention Delivery
monthsImmediate StartWaitlist Control
Feasibility of Participant Recruitment and Intervention Delivery88
PrimaryAcceptability of the Intervention by Study Participants

Acceptability will be assessed by measuring the number of diet counselling sessions completed. Additionally, participants will be asked to complete a brief satisfaction survey concerning the participant's level of satisfaction with the program, the aspects which were helpful or unhelpful, and opportunities for improvement. A sub-sample will be recruited to participate in a brief focus group in order to obtain more detailed qualitative responses about the participant experience and participant satisfaction.

Time frame:
12 weeks
Reported as:
Mean · number of sessions attended
Acceptability of the Intervention by Study Participants
number of sessions attendedImmediate StartWaitlist Control
Acceptability of the Intervention by Study Participants6.4 ± 1.56.4 ± 1.9
SecondaryAnxiety Symptom Severity: The Beck Anxiety Inventory

The Beck Anxiety Inventory is a validated 21-item self-report inventory for measuring the severity of anxiety in participants with psychiatric illness. Answers to each item are given a score of 0 (not at all), 1 (mild), 2 (moderate) or 3 (severely), total scores range from 0 to 63 (minimal anxiety levels (0-7), mild anxiety (8-15), moderate anxiety (16-25), and severe anxiety (26-63)). The Beck Anxiety Inventory will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.

Time frame:
12 weeks
Reported as:
Mean · units on a scale
Anxiety Symptom Severity: The Beck Anxiety Inventory
units on a scaleImmediate StartWaitlist Control
Baseline26.2 (22.94 to 29.48)29.3 (24.73 to 33.91)
12 weeks11.0 (8.05 to 13.87)26.8 (22.09 to 31.56)
SecondaryDiet Quality: MEDI-LITE Questionnaire

MEDI-LITE is a validated questionnaire that measures daily and weekly consumption of food typical and non-typical to the Mediterranean diet. Typical Mediterranean diet foods are scored 2 for high consumption, 1 more moderate and 0 for low. Non-typical Mediterranean diet foods are scored 2 for low consumption, 1 for moderate and 0 for high. Scores range from 0 (low consumption) to 18 (high consumption). The MEDI-LITE questionnaire will be completed to assess adherence to the Mediterranean diet at baseline, after the wait period (for those in the waitlist group) and after the intervention.

Time frame:
12 weeks
Reported as:
Mean · score on a scale
Diet Quality: MEDI-LITE Questionnaire
score on a scaleImmediate StartWaitlist Control
Baseline7.2 (6.32 to 8.10)7.1 (6.33 to 7.91)
12 Weeks10.5 (9.55 to 11.49)6.9 (6.17 to 7.74)
SecondaryQuality of Life: PROMIS-29 v2.1

The PROMIS-29 is a validated scale using 4 items scored on a 1-5 scale on intensity to assess 7 health domains (physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities and pain interference). Higher score equals more of the concept being measured (e.g., more Fatigue, more Physical Function). PROMIS-29 will be used to assess quality of life at baseline, after the wait period (for those in the waitlist group) and after the intervention.

Time frame:
12 weeks
Reported as:
Mean · score on a scale
Quality of Life: PROMIS-29 v2.1
score on a scaleImmediate StartWaitlist Control
physical, baseline4.54 (4.29 to 4.79)4.28 (3.93 to 4.63)
physical, 12 weeks4.79 (4.61 to 4.97)4.20 (3.82 to 4.56)
anxiety, baseline3.42 (3.18 to 3.65)3.55 (3.29 to 3.81)
anxiety, 12 weeks2.16 (1.81 to 2.52)3.25 (2.92 to 3.58)
depression, baseline2.59 (2.11 to 3.07)2.48 (2.03 to 2.95)
depression, 12 weeks1.72 (1.37 to 2.08)2.27 (1.83 to 2.72)
fatigue, baseline3.78 (3.45 to 4.12)3.69 (3.35 to 4.03)
fatigue, 12 weeks2.75 (2.32 to 3.18)3.53 (3.09 to 9.97)
social, baseline2.83 (2.38 to 3.28)2.81 (2.45 to 3.17)
social, 12 weeks3.79 (3.31 to 4.28)3.14 (2.66 to 3.62)
pain, baseline2.09 (1.59 to 2.59)2.24 (1.73 to 2.75)
pain, 12 weeks1.57 (1.19 to 1.96)2.14 (1.62 to 2.66)
SecondaryMindful Eating Behaviour: Mindful Eating Questionnaire

The MEQ is a 28-item scale that measures five factors associated with mindful eating (emotional responses, distraction, external cues, awareness and disinhibition). The questionnaire will be used to measure behaviour change and qualitatively assess the acceptability of the intervention. Each item is scored on a 1-4 scale, higher scores signify more mindful eating. The scores are added together and divided by the number of items answered to get a total summary score. The minimum score is 1 and the maximum score is 4. The MEQ will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.

Time frame:
12 weeks
Reported as:
Mean · units on a scale
Mindful Eating Behaviour: Mindful Eating Questionnaire
units on a scaleImmediate StartWaitlist Control
MEQ, baseline2.5 (2.38 to 2.73)2.6 (2.46 to 2.77)
MEQ, 12 weeks2.88 (2.73 to 3.03)2.5 (2.37 to 2.69)
SecondarySelf Efficacy: General Self-Efficacy Scale

The GSE is a 10-item validated questionnaire that measures an individual's belief in their ability to overcome and respond to difficult scenarios. Answers to each item are given a score of 0 (not at all true), 1 (barely true), 3 (moderately true) or 4 (exactly true), higher scores correlate to greater self-efficacy. The minimum score is 10 and the maximum score is 40. The GSE will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.

Time frame:
12 weeks
Reported as:
Mean · units on a scale
Self Efficacy: General Self-Efficacy Scale
units on a scaleImmediate StartWaitlist Control
GSE, baseline28.9 (27.24 to 30.59)28.2 (26.20 to 30.20)
GSE, 12 weeks32.3 (30.70 to 33.91)28.2 (26.49 to 29.95)
SecondaryOmegaScore

Summed EPA, DHA and DPA as a percentage of total fatty acids in whole blood as a measure of omega-3 status. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.

Time frame:
12 weeks
Reported as:
Mean · percentage
OmegaScore
percentageImmediate StartWaitlist Control
baseline3.58 ± 0.743.43 ± 0.50
week 127.18 ± 2.123.47 ± 0.92
SecondaryFasting Cholesterol Panel

Measures of serum cholesterol including LDL, HDL, triglycerides and total cholesterol. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.

Time frame:
12 weeks
Reported as:
Mean · mmol/L
Fasting Cholesterol Panel
mmol/LImmediate StartWaitlist Control
triglycerides, baseline1.13 (0.93 to 1.32)1.02 (0.89 to 1.15)
triglycerides, week 120.88 (0.69 to 1.06)0.88 (0.74 to 1.03)
Total cholesterol, baseline4.72 (4.24 to 5.19)4.80 (4.30 to 5.30)
Total cholesterol, week 124.62 (4.11 to 5.13)4.75 (4.32 to 5.18)
LDL, baseline2.63 (2.20 to 3.05)2.84 (2.42 to 3.74)
LDL, week 122.67 (2.21 to 3.57)2.86 (2.50 to 3.21)
HDL, baseline1.58 (1.40 to 1.75)1.50 (1.34 to 1.66)
HDL, week 121.55 (1.37 to 1.73)1.49 (1.32 to 1.67)
SecondaryHemoglobin A1c

Measure of the average blood sugar in the past 3 months. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.

Time frame:
12 weeks
Reported as:
Mean · percentage
Hemoglobin A1c
percentageImmediate StartWaitlist Control
baseline5.35 (5.23 to 5.46)5.52 (5.15 to 5.88)
12 weeks5.36 (5.24 to 5.48)5.57 (5.16 to 5.97)
SecondarySerum Vitamin C

Measure of serum levels of vitamin C as an objective marker for fruit and vegetable intake. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.

Time frame:
12 weeks
Reported as:
Mean · umol/L
Serum Vitamin C
umol/LImmediate StartWaitlist Control
baseline49.00 (41.55 to 56.45)41.36 (33.99 to 48.74)
week 1250.90 (43.17 to 58.64)42.25 (35.24 to 49.26)
SecondarySerum Beta-carotene

Measure of serum levels of beta-carotene as an objective marker for fruit and vegetable. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.

Time frame:
12 weeks
Reported as:
Mean · umol/L
Serum Beta-carotene
umol/LImmediate StartWaitlist Control
baseline0.53 (0.38 to 0.67)0.40 (0.29 to 0.52)
week 120.66 (0.49 to 0.83)0.44 (0.32 to 0.57)
SecondaryC-reactive Protein

CRP will be used to measure inflammation levels. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.

Time frame:
12 weeks
Reported as:
Mean · mg/L
C-reactive Protein
mg/LImmediate StartWaitlist Control
baseline3.11 (1.97 to 4.26)6.60 (2.77 to 10.43)
week 124.06 (2.27 to 5.85)7.49 (2.78 to 12.19)
SecondaryHOMA-IR

Homeostatic Model Assessment of Insulin Resistance, calculated using fasting insulin and fasting glucose. Formula: fasting glucose (mg/dL) X fasting insulin (mU/L) / 405. A higher value suggests more insulin resistance. These blood tests and calculation will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.

Time frame:
12 weeks
Reported as:
Mean · HOMA-IR index
HOMA-IR
HOMA-IR indexImmediate StartWaitlist Control
baseline2.94 (2.01 to 3.87)4.05 (1.86 to 6.25)
12 weeks2.92 (1.89 to 3.95)4.81 (0.93 to 8.69)

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Immediate Start0/25 (0%)0/25 (0%)21/25 (84%)
Waitlist Control0/25 (0%)0/25 (0%)0/25 (0%)
Most frequent other events
Most frequent other events
EventImmediate StartWaitlist Control
GI symptomsGastrointestinal disorders19/250/25
heart palpitationsCardiac disorders2/250/25
pruritisSkin and subcutaneous tissue disorders1/250/25

Baseline characteristics

Age, Continuous
Age, Continuous(years)Immediate StartWaitlistTotal
Mean39 ± 1435 ± 1037 ± 12
Sex: Female, Male
Sex: Female, Male(Participants)Immediate StartWaitlistTotal
Female242549
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Immediate StartWaitlistTotal
Black246
East/Southeast Asian303
First Nations/Indigenous/Metis101
Latino213
Middle Eastern101
South Asian134
White131427
Another race123
Do not know011
Baseline Beck Anxiety Inventory Score
Baseline Beck Anxiety Inventory Score(units on a scale)Immediate StartWaitlistTotal
Mean26.2 ± 8.1729.3 ± 11.7127.8 ± 10.1
08

Study locations

1 site
  • Canadian College of Naturopathic Medicine
    Toronto, Ontario M2K 1E2, Canada
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Nov 2023, 15 months.

Results were first posted in Apr 2025, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2022
First posted
Oct 10, 2022
StartActual
Aug 12, 2022
Primary completionActual
Nov 30, 2023
CompletionActual
Nov 30, 2023
Results first posted
Apr 4, 2025
Last update
Apr 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05573672
Lead sponsor
The Canadian College of Naturopathic Medicine
Collaborators
McGill University, Netherlands Open University, Massachusetts General Hospital, Ekhagastiftelsen, AquaOmega, Lipid Analytical Laboratories Inc, Mitacs
Responsible party
Sponsor
First posted
Oct 10, 2022
Start date
Aug 12, 2022
Primary completion
Nov 30, 2023
Completion
Nov 30, 2023
Results posted
Apr 4, 2025
Last update
Apr 4, 2025

Study contacts

Monique Aucoin, ND MSc
principal investigator · Canadian College of Naturopathic Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion